Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’
Crossref DOI link: https://doi.org/10.1038/eye.2015.191
Published Online: 2015-10-09
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Homer, N
Grewal, D S
Mirza, R G
Lyon, A T
Gill, M K
Text and Data Mining valid from 2015-10-09
Article History
First Online: 9 October 2015
Competing interests
: The authors declare no conflict of interest.